Jean-Yves Douillard
Overview
Explore the profile of Jean-Yves Douillard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
137
Citations
9702
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cohen R, Raeisi M, Chibaudel B, Shi Q, Yoshino T, Zalcberg J, et al.
Eur J Cancer
. 2024 Jun;
207:114160.
PMID: 38896997
Background: The liver is the most frequent site of metastases in colorectal cancer (CRC). This study aimed to assess the response rate and survival outcomes in metastatic CRC patients with...
2.
Cazeneuve N, Bouche O, Leger J, Borg C, Labbe-Devilliers C, Lucidarme O, et al.
Clin Res Hepatol Gastroenterol
. 2024 May;
48(7):102380.
PMID: 38788975
Background: Visceral fat produces angiogenic factors such as vascular endothelial growth factor that promote tumoral growth. However, its influence on outcome for patients with advanced cancer treated with anti-angiogenic agents...
3.
Ou F, Ahn D, Dixon J, Grothey A, Lou Y, Kasi P, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627145
Patients And Methods: Patients enrolled in 17 first-line clinical trials, who had mCRC with ≥ 2 lesions at baseline, and a restaging scan by 12 weeks were included. For each...
4.
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J, et al.
J Clin Oncol
. 2023 Feb;
41(6):1162-1171.
PMID: 36791474
Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated...
5.
Mikhail Lette M, Paez D, Shulman L, Guckenberger M, Douillard J, Oyen W, et al.
JCO Glob Oncol
. 2022 Jun;
8:e2100100.
PMID: 35649215
Purpose: Key to achieving better population-based outcomes for patients with lung cancer is the improvement of medical imaging and nuclear medicine infrastructure globally. This paper aims to outline why and...
6.
Papamichael D, Lopes G, Olswold C, Douillard J, Adams R, Maughan T, et al.
Eur J Cancer
. 2022 Jan;
163:1-15.
PMID: 35033994
Purpose: Colorectal cancer (CRC) affects many older adults. We investigated the efficacy and safety of adding anti-epidermal growth factor receptor (EGFR) agents to doublet chemotherapy (DC) in older patients. Methods:...
7.
Cohen R, Liu H, Fiskum J, Adams R, Chibaudel B, Maughan T, et al.
J Natl Cancer Inst
. 2021 Mar;
113(10):1386-1395.
PMID: 33734401
Background: First-line therapeutic strategies for patients with BRAFV600E-mutated (BRAFmt) metastatic colorectal cancer (mCRC) mainly rely on subgroup analyses from randomized controlled trials (RCTs). We aimed to assess the prognostic and...
8.
Rauh S, Mavroeidis L, Ntellas P, Gazouli I, Gkoura S, Papadaki A, et al.
ESMO Open
. 2021 Feb;
5(1):e000615.
PMID: 33551069
No abstract available.
9.
Sessa C, Colombo N, Creutzberg C, Concin N, Wimberger P, Curigliano G, et al.
ESMO Open
. 2020 Nov;
5(6):e001130.
PMID: 33239316
No abstract available.
10.
Metges J, Douillard J, Ramee J, Dupuis O, Senellart H, Porneuf M, et al.
Turk J Gastroenterol
. 2020 Nov;
31(10):695-705.
PMID: 33169707
Background/aims: The Bretagne-Pays de la Loire cancer observatory, an oncology network created by the French Ministry of Health, is specifically dedicated to assess the use of new targeted anticancer therapies...